Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Miscalibration of venous thromboembolic risk assessment models across race and ethnicity in medical patients: A cross-model analysis, correction strategy and potential mediators

John Quigley, Ryan Sun, Ahmad Nassar et al. Nov 03, 2025 pp. 4397-4397 10.1182/blood-2025-4397

Abstract Background: Hospital-associated venous thromboembolism (VTE) affects 350,000 US patients annually and is the leading cause of preve...

Expression of the erythroid controller of systemic iron homeostasis erythroferrone is cis-regulated

Robert Sertori, Gemma Moir-Meyer, Cavan Bennett et al. Nov 03, 2025 pp. 528-528 10.1182/blood-2025-528

Abstract Erythroferrone (ERFE) is secreted from erythroblasts in response to increased erythropoiesis to suppress hepcidin, enabling enhance...

Poor prognosis of immunosuppressive therapy in patients with bone marrow failure-related germline mutations combined with BCOR/L1 Mutations

Nanxi Dong, Jingjing Liu, Yingying Shen et al. Nov 03, 2025 pp. 6718-6718 10.1182/blood-2025-6718

Abstract Introduction Non-severe aplastic anemia (NSAA) shows varied treatment responses and outcomes. While clonal mutations' role in disea...

Fapi PET/CT as an innovative imaging tool for monitoring bone marrow fibrosis and treatment response in myelofibrosis patients undergoing allogeneic stem cell transplantation

Victoria Panagiota, Simon Kroehn, Thomas Francke et al. Nov 03, 2025 pp. 4303-4303 10.1182/blood-2025-4303

Abstract Background: Myelofibrosis (MF) is a clonal myeloproliferative neoplasm, characterized by progressive bone marrow fibrosis driven by...

A phase 1/2 study of GB3226, a novel dual inhibitor of ENL-yeats and FLT3, in patients with relapsed/refractory Acute Myeloid Leukemia

Abhishek Maiti, Richard Schlenk, Brian Jacoby et al. Nov 03, 2025 pp. 1652-1652 10.1182/blood-2025-1652

Abstract Background: Acute myeloid leukemia (AML) remains a formidable challenge in hematology, particularly for patients with relapsed or r...

KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)

Jessica Leonard, Abdullah Ladha, Rawan Faramand et al. Nov 03, 2025 pp. 3365-3365 10.1182/blood-2025-3365

Abstract Introduction: Brexu-cel is a highly effective treatment for R/R B-ALL, with complete responses achieved in 71%...

Functional investigation into NK cells identifies salt-inducible kinases as novel therapeutic targets against NK malignancies

Arindam Ray, Lulu Wang, Chenyang Yu et al. Nov 03, 2025 pp. 53-53 10.1182/blood-2025-53

Abstract Background: Natural Killer (NK) cells are innate lymphoid cells that play critical roles in anti-tumor and anti-viral immunity. How...

Do patients with classic Hodgkin's lymphoma treated with ABVD in low-middle income countries have a higher risk of neutropenia/febrile neutropenia without G-CSF support? a single-center retrospective study

Barbara Galvão, Andre Meireles, Paloma Resende et al. Nov 03, 2025 pp. 6338-6338 10.1182/blood-2025-6338

Abstract Introduction: Patients with Hodgkin lymphoma (cHL) who receive adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) chemother...

Association of duffy antigen receptor for chemokines with clinical conditions: A scoping review

Tharani Anpalagan, Damilola Ojo Shittu, Jenna Segall et al. Nov 03, 2025 pp. 6551-6551 10.1182/blood-2025-6551

Abstract Introduction: The Duffy antigen receptor for chemokines (ACKR1) is found on erythrocytes and appears to function as a chemokine sin...

Global immunopeptidome remodeling favors piga mutant clones in bone marrow failure

Kartik Lakhotiya, Xiaorong Gu, Arda Durmaz et al. Nov 03, 2025 pp. 3207-3207 10.1182/blood-2025-3207

Abstract The basis of PNH immune privilege remains elusive. Various models have been proposed, each consistent with some but not all clinica...

C-CBL mutations affecting residue 371 confer dismal prognosis in MDS and CMML

Luca Guarnera, Carmelo Gurnari, Zachary Brady et al. Nov 03, 2025 pp. 2064-2064 10.1182/blood-2025-2064

Abstract In myeloid neoplasm (MN), c-CBL missense mutations affecting the linker region and zinc finger domains (LR/ZF, 352-420 residues) im...

Rates of inhibitor development and immune tolerance in children with severe Hemophilia A on emicizumab prophylaxis

Anna Schwartz, Bhavya Doshi, Karen Zimowski et al. Nov 03, 2025 pp. 4851-4851 10.1182/blood-2025-4851

Abstract Introduction: Congenital hemophilia A (HA) is a genetically inherited bleeding disorder caused by pathologic variants in the F8 gen...

Relationship between KIT inhibition by bezuclastinib and effects on disease burden in mouse models of systemic mastocytosis

Michelle Crow, Karyn Bouhana, Eric Brown et al. Nov 03, 2025 pp. 5531-5531 10.1182/blood-2025-5531

Abstract Background: Nonadvanced Systemic Mastocytosis (NonAdvSM) is primarily driven by activating mutations in the KIT proto-oncogene, wit...

Optimizing PNH treatment with the complement inhibitor pegcetacoplan: A case report

Edo Schaefer, Peter Blandino, Peter Hillmen et al. Nov 03, 2025 pp. 6734-6734 10.1182/blood-2025-6734

Abstract Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, serious hematologic disorder characterized primarily b...

Enhanced FLI1 accessibility mediates STAG2-mutant leukemogenesis

Jane J Xu, Viviana Scoca, Yi Chen et al. Nov 03, 2025 pp. 1467-1467 10.1182/blood-2025-1467

Abstract Hematopoietic stem cells (HSCs) are multipotent cells that can give rise to all blood cell types. In leukemia, HSCs are often the c...

A scoring system for epstein-barr reativation after hematopoietic stem cell transplantation

Xinyu Wang, Yanmin Zhao, Jingsong He et al. Nov 03, 2025 pp. 7811-7811 10.1182/blood-2025-7811

Abstract Objective: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for hematological malignancies....

Haploidentical hematopoietic cell transplantation (Haplo-HCT) using ex vivo TCR-αβ–Depleted grafts and upfront memory T-cell add-back mitigates the negative impact of pre-transplant measurable residual disease (MRD) in adults with Acute Myeloid Leukemia (AML) and acute lymphoblastic leukemia (ALL) compared to matched related and unrelated donor transplantation

Evelyn Aun, Victor Ling Wei Teik, Yeh-Ching Linn et al. Nov 03, 2025 pp. 6020-6020 10.1182/blood-2025-6020

Abstract Background Previous studies have shown that in patients receiving allogeneic hematopoietic cell transplantation (HCT) from either a...

Same outcomes, different odds: Socioeconomic disparities in PMBCL care across u.S. cancer centers

Laura Reyes-Uribe, Carolina Velez-Mejia, Ysaith Orellana Ascencio et al. Nov 03, 2025 pp. 5445-5445 10.1182/blood-2025-5445

Abstract Background: Primary mediastinal large B-cell lymphoma (PMBCL) is a distinct and aggressive subtype of large B-cell lymphoma that ar...

Multimodal single-cell and spatial analyses reveal a distinct immune ecosystem in pediatric classic Hodgkin lymphoma

Shinichiro Oshima, Yifan Yin, Nawar Dakhallah et al. Nov 03, 2025 pp. 3552-3552 10.1182/blood-2025-3552

Abstract Introduction: Classic Hodgkin lymphoma (CHL) is unique among most malignancies as the malignant Hodgkin and Reed–Sternberg (HRS) cel...

A clinical study on the Efficacy and safety of luspatercept in Chinese patients with non-transfusion-dependent β-thalassemia

He Li, Ting Niu, XINMEI YU et al. Nov 03, 2025 pp. 1142-1142 10.1182/blood-2025-1142

Abstract Background: β-thalassemia is a hereditary anemia caused by insufficient hemoglobin production due to reduced or complete absence of...

BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter, showing promising efficacy in T cell lymphoma patients

Stefan Barta, Christiane Querfeld, Sean Lim et al. Nov 03, 2025 pp. 3633-3633 10.1182/blood-2025-3633

Abstract Background: T-cell lymphomas (TCL) make up about 10-15% of all Non-Hodgkin's Lymphomas (NHLs), with peripheral T-cell lymphoma (PTC...

Metabolic conditioning for enhanced CAR T cell function

Yufan Zhou, Andre Kelly, Tyler Quarton et al. Nov 03, 2025 pp. 4127-4127 10.1182/blood-2025-4127

Abstract Introduction Durable benefits in adoptive immunotherapies are often linked to metabolic reprogramming, differentiation states, and...

Autologous hematopoietic stem cell transplantation followed by CD19/CD22 dual-target CAR-T therapy for refractory or relapsed burkitt lymphoma

Xian Zhang, Lin Wang, Xiangqun Li et al. Nov 03, 2025 pp. 5924-5924 10.1182/blood-2025-5924

Abstract Background Relapsed and refractory (R/R) Burkitt's lymphoma is characterized by its aggressive nature and poor prognosis. Autologou...

Incidence, risk factors, and survival impact of secondary myelofibrosis in patients with myeloproliferative neoplasms in the real world: A nested case-control study

Yuhui Zhang, Guangshuai Teng, Yunhan Zhao et al. Nov 03, 2025 pp. 7337-7337 10.1182/blood-2025-7337

Abstract Myeloproliferative neoplasms (MPN) are a group of diseases characterized by clonal proliferation of hematopoietic stem cells in the...

Gut colonization with MDR gram negative organisms and its impact on bacteremia and sepsis development among children with hematological malignancies

Reham Khedr, Nadine Abdelwahab, dalia kadry et al. Nov 03, 2025 pp. 5170-5170 10.1182/blood-2025-5170

Abstract Background: Gut colonization with multidrug-resistant organisms (MDROs) is a well-established risk factor for b...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page